217 completed, 20 unknown, 18 terminated, 5 recruiting. 69 Phase 4, 62 Phase 1, 61 Phase 3, 27 Phase 2, 13 Not applicable.
Follow Telmisartan: new trials by email Literature Review of Telmisartan trials Research Report on Telmisartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension Eplerenone, Telmisartan - Hypertension (HTN), Low-Renin Essential Hypertension | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 128 | 2026-12-01 | 2026-11-12 |
| A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers Atorvastatin Calcium, Telmisartan - Drug-drug Interactions | Phase 1 | Not yet recruiting | Huons Co., Ltd. | 28 | 2026-09-01 | 2026-09-10 |
| Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors Telmisartan, Metformin, Cilostazol - Stroke | Early Phase 1 | Recruiting | Spaulding Rehabilitation Hospital | 50 | 2026-05-18 | 2026-07-14 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients Telmisartan, Doxorubicin (DOX) - Breast Cancer, Doxorubicin Induced Cardiomyopathy | Phase 1 / Phase 2 | Not yet recruiting | Tanta University | 36 | 2026-02-01 | 2026-01-29 |
| Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Telmisartan - Ovarian Cancer | Phase 2 | Recruiting | Tyler J Curiel | 33 | 2026-01-21 | 2026-01-28 |
| Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD) | Phase 3 | Recruiting | University College, London | 1200 | 2025-09-12 | 2025-10-03 |
| A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension THP-00101, THP-00102, THP-00103 - Type 2 Diabetes, Hypertension | Phase 3 | Active not recruiting | THPharm Corp. | 222 | 2025-04-10 | 2026-11-09 |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| Telmisartan in Prostate Cancer Telmisartan, Standard of Care Regimen - Prostate Cancer | Phase 1 | Recruiting | Tyler J Curiel | 36 | 2024-04-22 | 2026-07-22 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg - Essential Hypertension | Phase 4 | Active not recruiting | Yuhan Corporation | 198 | 2023-10-18 | 2026-02-13 |
| A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin. THP-00101 (Dapagliflozin) 10mg, THP-00102 (Telmisartan) 80mg - Hypertension, Diabetes Mellitus, Type 2 | Phase 1 | Completed | THPharm Corp. | 51 | 2023-10-09 | 2023-11-22 |
| To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun - Metabolic Syndrome | Not applicable | Unknown | Hamdard University | 200 | 2023-09-01 | 2024-07-23 |
| Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension Egito, Empagliflozin + telmisartan - Hypertension Associated, Type II Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2023-08-01 | 2023-09-08 | |
| A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome Telmisartan, Losartan - Essential Hypertension, Metabolic Syndrome | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 116 | 2023-06-01 | 2023-05-06 |
| Improving 24-hour Blood Pressure in Obstructive Sleep Apnea Continuous Positive Airway Pressure CPAP, Telmisartan 80mg, Alpha-Lipoic Acid 600mg - Obstructive Sleep Apnea | Early Phase 1 | Withdrawn | University of British Columbia | 2023-05-01 | 2023-05-19 | |
| Efficacy and Safety of Telmisartan Compared With Losartan telmisartan, Losartan - Diabetic Nephropathies, Hypertension | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 98 | 2023-04-19 | 2024-05-28 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension Telmisartan/Amlodipine/Chlorthalidone(Truset) - Essential Hypertension | Active not recruiting | Yuhan Corporation | 1219 | 2022-06-08 | 2024-11-19 | |
| Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice subjects treated with telmisartan/hydrochlorothiazide, Subjects treated with Telmisartan and amlodipine, subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group - Hypertension | Withdrawn | Boehringer Ingelheim | 2022-06-01 | 2022-06-28 |
Showing 20 of 273. Sign in to see all of them.
Hypertension (159) · Essential Hypertension (15) · COVID-19 (10) · Diabetes Mellitus, Type 2 (10) · Hyperlipidemias (9) · Metabolic Syndrome (8) · Cardiovascular Diseases (6) · Dyslipidemias (6) · Stroke (6) · Coronary Artery Disease (5) · Diabetic Nephropathies (5) · Obesity (5) · Renal Insufficiency, Chronic (5) · Insulin Resistance (4) · Atrial Fibrillation (3)
Boehringer Ingelheim (118) · Yuhan Corporation (15) · Chong Kun Dang Pharmaceutical (11) · Bayer (9) · IlDong Pharmaceutical Co Ltd (5) · Jeil Pharmaceutical Co., Ltd. (5) · The George Institute (4) · Addpharma Inc. (3) · Brigham and Women's Hospital (3) · ANRS, Emerging Infectious Diseases (2) · Daewon Pharmaceutical Co., Ltd. (2) · George Medicines PTY Limited (2) · HK inno.N Corporation (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · THPharm Corp. (2)
South Korea (62) · United States (38) · Japan (21) · Germany (20) · France (18) · Canada (16) · Italy (14) · China (13) · Spain (13) · Australia (11) · Netherlands (11) · United Kingdom (10) · Denmark (9) · Mexico (9) · Slovakia (9)
Anthony Rodgers, Professor (2) · Arlene Chapman, M.D. (2) · Hyo Soo Kim, M.D., Ph.D (2) · Kyun S Bae, Ph.D. (2) · Marva Moxey-Mims, M.D. (2) · Nittaya Phanuphak, MD, PhD (2) · Ramon C Hermida, PhD (2) · Robert Schrier, M.D. (2) · Ronald Perrone, M.D. (2) · Shirley Wang, PhD, ScM (2) · Vicente Torres, M.D. (2) · Young-Ran Yoon (2)
PMID 38682786, PMID 22721873, PMID 32905623, PMID 34473343, PMID 36398903, PMID 39356039, PMID 14630977, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 17339550, PMID 17389151, PMID 18378520, PMID 18496508, PMID 18537808, PMID 18707986, PMID 18753638, PMID 18753639, PMID 18757085, PMID 18757238, PMID 19100670, PMID 19191674, PMID 19407805, PMID 19451556, PMID 19463506, PMID 19506526, PMID 19683638, PMID 19770395, PMID 20231536, PMID 20980201, PMID 21070920, PMID 21200437, PMID 21252701, PMID 21263104, PMID 21357827, PMID 21617110, PMID 21700754, PMID 21788624, PMID 21884956, PMID 21947289, PMID 22089721, PMID 22090469, PMID 22192672, PMID 22205355, PMID 22267825, PMID 22329591, PMID 22495138, PMID 22525206
2008 (4), R01NS084911 (2), U01DK062401 (2), U01DK082230 (2), 1RF1AG051514 (1), 2009 (1), 2015 (1), 2023 (1), R01HL126117 (1), R01MH095613 (1), R01MH104141 (1), U54MD007601 (1), UM1AI068636 (1)